News | January 09, 2026
Alkem launches innovative hair growth support therapy kit
The supplements are made using only vegetarian-sourced ingredients
The supplements are made using only vegetarian-sourced ingredients
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Subscribe To Our Newsletter & Stay Updated
